Phenicols Market Size, Share & Trend | Industry Report, 2017-2025

Antibacterial drug is defined as an agent that interferes with the growth and reproduction of bacteria that can cause numerous mild-to-severe infections in living organisms. Antibacterial drugs have bactericidal action. They act on various parts of the bacterial life cycle such as protein synthesis, nucleic acid synthesis, cell wall synthesis, and permeability of cell membrane. Thus, they help in treating infections. These drugs have been classified into eight major classes viz. aminoglycosides, β-lactams, tetracycline, sulfonamides, quinolones/fluoroquinolones, macrolides, and phenicols. Phenicols, a broad spectrum antibacterial drugs, is a major class of antibacterial drugs. Phenicols are bacteriostatic in their mode of action. Molecules of phenicols inhibit the elongation step of the bacterial protein synthesis by binding to peptidyl transferase. Phenicols are highly effective against gram positive, gram negative, aerobic and anaerobic bacterial strains. These drugs are specifically used to treat infections caused by Chlamydia, Mycoplasma, and Rickettsiae species. Also, this class of antibacterial drugs is not commonly prescribed to treat simple infections such as flu, cold, and sore throat and other minor infections.

Request to view Sample Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37232

Phenicols are utilized in treating serious bacterial infections (such as meningitis), wherein other medicines do not work, as these drugs are capable of crossing the blood–brain barrier. Phenicols are also employed in combination with other antibacterial drugs in order to increase the overall effectiveness of the treatment. However, they may cause some side–effects, which may lead to unusual bleeding, bruising, or eye-related problems. Growth drivers for the phenicols market include increasing prevalence of highly potent and serious bacterial infections and rising availability of generics in emerging as well as developed markets. Moreover, governments of different countries have initiated various developmental programs to accelerate innovations in antibacterial drugs in order to address the need for better treatment of harmful infections and to overcome rapid development of antibiotic-resistant species. However, patent expiry of drugs and bacterial drug resistance are major restraints for the phenicols market. Certain side-effects associated with long-term use of phenicols have also caused hindrance to use of phenicols for the treatment of infectious diseases.

The global phenicols market can be segmented based on route of administration, distribution channel, and region. Based on route of administration, the global phenicols market can be segmented into oral route and intravenous route. Based on distribution channel, the market can be divided into hospital pharmacies, retail pharmacies, and clinics.

Geographically, the global phenicols market can be segregated into five major regions: North America, Asia Pacific (APAC), Europe, Latin America, and Rest of World (RoW). Asia Pacific is expected to dominate the global phenicols market during the forecast period. Expanding health care infrastructure, rising disposable income, and large geriatric population in emerging economies such as India and China are some of the factors expected to play a key role in making Asia Pacific a highly attractive market for manufacturers operating in the phenicols market during the forecast period. Presence of leading manufacturers of generic drugs, low cost of clinical trials, and rapidly expanding pharmaceutical industry in the region would propel the market in Asia Pacific in the next few years.

New drugs are usually launched in the U.S. or Europe market before other parts of the world. This early market initiation results in a larger market share held by North America and Europe. Continuous research and development activities in the drug discovery industry would propel the phenicols market during the forecast period. Major players operating in the global phenicols market are GlaxoSmithKline plc, Sanofi, Pfizer, Inc. and Fresenius Kabi AG.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

View Report @ https://www.transparencymarketresearch.com/phenicols-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com

This release was published on openPR.